Column: Why there cannot be a complete cure for cancer – but there is certainly another way!

"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.

Björn Ursing: Physicians new role in AI driven healthcare

”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians cha...

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...

Anna Törner: Success requires bold decisions!

“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.

Hello Angelica Loskog!

Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.

Opinion: Where do all the cool Swedish life science companies go?

It’s puzzling why Swedish life science companies hardly get a mention alongside Spotify, Skype, Klarna, King, iZettle, and other cool, innovative and successful...

How critical are the “Spermageddon” reports? – Researchers call for action

A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden s...

Pharma-on-Demand

Make or buy? That is the question that the pharma world has been asking more and more in the last couple of decades. Pernille Hemmingsen is moderator at Pharma ...

Swedish life science in political focus

It feels like 2017 will be a good year for Swedish life science, says Anders Blanck, CEO at LIF.

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.

Anna Törner: Mitt i ett äventyr

”Att lyckas tillsammans med andra är en berusande känsla”. Det skriver Anna Törner som efter åtta år som vd för SDS nu lämnat över stafettpinnen.

Första läkemedlet för bara en patient

I en ny artikel beskrivs det förmodade första fallet av ultra-personalized medicine – ett läkemedel till en åttaårig flicka med en ovanlig genetisk sjukdom.

Han är bäst på forskningspresentation

Ki-forskaren Peter Ueda vann årets Forskar grand prix och tog därmed hem titeln som svensk mästare i att presentera sin egen forskning.

Krönika: Collaboration across borders

Go ahead for leg wound study

Tripep starts a phase II-study of their wound healing joint venture project.

Pygargus får ny vd

Patrik Sobocki blir dataanalys-företagets nya vd från och med den 7 mars.

Nya kit för genetiska fingeravtryck

Qiagens Investigator-serie tar fram genetiska fingeravtryck vid exempelvis brottsutredningar.

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...

Bioresonator prisas för globaliseringsplan

Hade bäst strategi i Stings program Go global medtech.

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Vivoline vinner medtechpris

Medicinteknikföretaget Vivoline vann pris för bäst internationaliseringsplan i årets Go Global Medtech-program som anordnats av inkubatorn Sting.

Bioresonator i konkurs

Efter en tid med finansiella problem går Allenex portföljbolag i graven.